Table 2 Markers that are shown to be associated with phenotype traits either at close to the claimed genome-wide significant p-value of ≤3.41 × 10−08 or at nominally significant p-value of ≤5.45 × 10−07.

From: Genetic risk variants for metabolic traits in Arab populations

Phenotype

Variant

Gene

Model

MAF

Beta $

P-value $

Beta #

P-value #

Bonferroni p-value

Benjamini–Hochberg FDR p-value

A. Association at close to genome-wide significance of p-value ≤ 3.41E-08

HbA1c

chr15:40531386-rs12440118

ZNF106 (W > R)

Recessive

0.1059

2.006

7.07E-08

1.498

2.70E-05

0.003

0.0032

B. Associations at nominal significance of p-value ≤ 5.45E-07

 

rs7144734

OTX2-AS1 (upstream)

Recessive

0.2036

1.465

2.82E-07

1.361

4.31E-07

0.012

0.012

TGL

rs17501809

PLGRKT (intronic)

Recessive

0.0593

1.807

1.04E-07

1.74

3.29E-07

0.0047

0.0016

TGL

rs11143005

LOC105376072 (intronic)

Recessive

0.2829

0.4196

4.03E-07

0.4225

3.21E-07

0.018

0.0030

TGL

chr12:101494770/rs10860880

IGF1 (downstream)

Recessive

0.05575

1.596

2.077–07

1.603

1.74E-07

0.0095

0.0019

TGL

rs900543

THSD4, NR2E3 (intergenic/downstream to NR2E3)

Recessive

0.08696

1.625

1.27E-07

1.607

1.67E-07

0.0058

0.0016

  1. $Tests for association were adjusted for age, sex, and the first 10 principal components.
  2. #Tests for association with anthropometric and lipid traits were adjusted for age, sex, principal components, and lipid lowering medication status; tests for association with HbA1c and FGL were adjusted for age, sex, principal components, and diabetes medication status; tests for association with SBP and DBP were adjusted for age, sex, principal components, and hypertension medication status.